LENZ Therapeutics Reports Positive Phase 3 Results For LNZ100 In Presbyopia Trial In China

(RTTNews) – Corxel Pharmaceuticals and LENZ Therapeutics (LENZ) announced positive topline data from the Phase 3 JX07001 clinical trial of LNZ100 in patients with presbyopia in China.

In this China Phase 3 safety and efficacy trial, LNZ100 (1.75% aceclidine HCl) achieved the primary endpoint and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters).

The results indicated that 84% and 69% of participants achieved two-line and three-line improvements in visual acuity at 30 minutes, respectively. At three hours post-treatment, 88% and 74% demonstrated similar improvements, while maintaining their optimal distance visual acuity (defined as not losing five or more letters). Additionally, at 10 hours, 61% and 30% achieved two-line and three-line improvements, respectively.

LNZ100 was well-tolerated with no serious treatment-related adverse events observed in the trial.

The company noted that 91% of participants indicated they noticed an improvement in their near vision.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.